D. Cheung

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.

José Miguel Contreras, G. Lip, J. De Sutter, 2021, The lancet. Diabetes & endocrinology.

A Randomized, Double‐Blind, Active‐ and Placebo‐Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout

Robert L. Martin, C. Mcwherter, Heather L Williams, 2016, Arthritis & rheumatology.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Diane M. Miller, Natalia E. Shilkina, M. C. Cantero, 2018, Lancet.